EGFR and viral infectious disease: Taken together, our results demonstrate the activation of the RAS–MAPK pathway in response to spike protein binding, that EGFR is a novel cofactor of ACE2 that promotes SARS-CoV-2 entry and that inhibition has potential to reduce viral infection.